This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal

Rotavirus Vaccinesa are part of the HEDIS Combo 101

By age 2, children are recommended to have received at least 10 vaccines to help prevent different diseases.2 HEDIS measures the percent of children 2 years of age who have received 10 specific vaccines.1

aThere are two approved rotavirus vaccines in the US. For Rotatvirus – HEDIS Combo 10 measures include 2 doses or 3 doses depending on brand selected.1

NCQA Childhood Immunization Status

NCQA Childhood Immunization Status Combo 10:

Learn more

Healthy People 2030 Objective:

Reduce the proportion of children who get zero recommended vaccines by age 2 years.3

Rotavirus vaccination versus Combo 10 vaccination rates

Are rotavirus vaccination rates the key driver for lower Combo 10 HEDIS scores?

National Average Rates: Rotavirus Vaccination vs Combo 10 Vaccination1

Rotavirus Vaccination Rates by National Average Versus Combination 10 Vaccines on Medicaid HMO From 2019-2022
Rotavirus Vaccination Rates by National Average Versus Combination 10 Vaccines on Commercial HMO and PPO From 2019-2022

Based on these data, rotavirus vaccination rates appear to be higher than the national average Combo 10 vaccination rates and do not appear to be the main driver of the lower Combo 10 vaccination rates.

Data shown above reflect completed series of both rotavirus vaccines approved in the US.1,4

Number of doses needed for rotavirus vaccination series completion depends on which of the two available vaccines is selected.1,4

HEDIS, Healthcare Effectiveness Data and Information Set; NCQA, National Committee for Quality Assurance

CDC recommendations

Find out about the CDC recommendations for rotavirus vaccination in pediatric patients.2

See the CDC recommendations

Storage and handling

Find out how to store and handle RotaTeq in your practice.

Learn more

References

  1. Childhood Immunization Status – NCQA. NCQA. Published 2018. Accessed November 5, 2025. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/
  2. Advisory Committee on Immunization Practices (ACIP). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Last reviewed October 7, 2025. Accessed October 27, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
  3. Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services. Reduce the proportion of children who get no recommended vaccines by age 2 years — IID‑02 – Healthy People 2030. Accessed October 27, 2025. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/reduce-proportion-children-who-get-no-recommended-vaccines-age-2-years-iid-02
  4. Rotarix. Prescribing Information. GlaxoSmithKline; 2024

Indications and Usage

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Selected Safety Information

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

Infants with a history of intussusception should not receive RotaTeq.

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.

Indications and Usage
Selected Safety Information

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Selected Safety Information

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

Infants with a history of intussusception should not receive RotaTeq.

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.